Drug
Nnc0113 2023
Nnc0113 2023: highest development phase Phase 1, developed by Novo Nordisk. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Novo Nordisk
Trials
| Drug | Phase | Indication |
|---|---|---|
| NNC0113-2023 NCT03617081 | Phase 1 | Diabetes Mellitus, Type 2 |
Latest
No recent events.
Follow Nnc0113 2023 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.